Skip to content
type1.science

ELSA (EarLy Surveillance for Autoimmune diabetes)

University of Birmingham (co-funded by Diabetes UK and Breakthrough T1D)

A UK research programme testing whether childhood general-population screening for islet autoantibodies is feasible and acceptable at national scale. A home or clinic finger-prick dried blood spot detects the immune markers of T1D years before symptoms; children with two or more autoantibodies are staged by glucose test. It aims to find at-risk children beyond families with a history, prevent crisis (DKA) at diagnosis, and open the door to monitoring and prevention therapy — building the blueprint for a future NHS screening programme.

Available nowStrong evidencescreeningautoantibodypopulation-baseddried-blood-spotpaediatricukearly-detectiondka-prevention

The scorecard

Predictive value88

Built on validated staging: islet autoantibodies predate clinical T1D by 10-15 years and two or more confer near-lifetime certainty of progression; the assay is 89% sensitive / 100% specific on dried blood spot.

Actionability82

Early detection cuts DKA at onset (from as high as 40% to under 5% in comparable programmes), enables monitoring and education, and routes families toward prevention trials and the now-licensed delay therapy teplizumab.

Reach90

Explicitly general-population (not relatives-only), targeting 2-17 year-olds across all four UK nations with deliberate recruitment in deprived and underserved communities — directly addressing that most new T1D has no family history.

Low burden85

A single home, school or GP finger-prick dried blood spot returned by post; only the 1-2% who screen positive need a venous confirmation and glucose test.

Access & cost55

Free and open UK-wide while recruiting, but it is a time-limited research study, not yet a funded national programme; cost-effectiveness work to inform an NHS rollout is still pending.

The full picture

ELSA (EarLy Surveillance for Autoimmune diabetes) is a UK research programme, led from the University of Birmingham and co-funded by Diabetes UK and Breakthrough T1D, that tests whether screening the general childhood population for type 1 diabetes (T1D) is feasible and acceptable enough to become a national NHS service.1 It is not a treatment — it is the front door to early detection.

What is screened, and the staging model

The immune attack behind T1D produces islet autoantibodies that appear in the blood 10-15 years before any symptom; finding two or more means future insulin-requiring T1D is almost certain.1 ELSA measures these with a finger-prick dried blood spot that families can do at home, at school, at the GP or in hospital, then post back — far less burdensome than a clinic blood draw.1 A positive screen is confirmed by a venous test, and children with two or more autoantibodies have an oral glucose tolerance test to stage the disease: Stage 1 (autoantibodies, normal glucose), Stage 2 (autoantibodies plus dysglycaemia), and Stage 3 (clinical diabetes) — a staging framework now embedded in international guidelines and diagnostic codes.1

Who, predictive value and reach

ELSA screens children and young people aged 2-17 across England, Scotland, Wales and Northern Ireland, deliberately recruiting in deprived and underserved communities — because most new T1D occurs in people with no family history, which family-only screening misses.23 The original protocol set out to screen 20,000 children aged 3-13 and was statistically powered to find about 60 (0.3%) with early-stage T1D, an autoantibody prevalence anchored to Germany's Fr1da study, which found presymptomatic T1D in 0.31% of 90,632 children.14 The assay ELSA validated on dried blood spots is 89% sensitive and 100% specific.1

What early detection enables (and the DKA case)

The biggest immediate prize is avoiding diabetic ketoacidosis (DKA) — the dangerous, sometimes fatal crisis in which over a quarter of UK children are still diagnosed.3 Screening programmes abroad have cut DKA at onset from as high as 40% to under 5%.4 Children ELSA finds early arrive in much gentler shape — one case series reported a median HbA1c of 6.6% and low insulin needs — though a few progressed quickly, underlining why symptom education accompanies every result.5 Early knowledge also gives families time to prepare and unlocks access to monitoring and prevention trials.1

Safety, cost and acceptability

Risks are modest: the finger-prick is low-pain, only the 1-2% who screen positive need invasive follow-up, and a real concern — parental anxiety after a positive result — was shown to fade within 12 months in earlier studies, with counselling and psychology support built into ELSA.1 The honest limitation is access: ELSA is a time-limited study, not yet a funded national programme, and its feasibility and cost-effectiveness findings are designed to inform that decision.6

What's coming

In 2026, ELSA's team reported the feasibility results of UK general-population screening, providing what commentators called a "blueprint" for a national programme.7 The case for screening is strengthened by teplizumab, the first therapy shown to delay T1D — by a median of about two years in at-risk people — now licensed by the MHRA in the UK (age 8+) and FDA-approved since 2022, with a NICE decision on NHS funding still pending.89 Screening is the prerequisite that makes such a therapy usable at scale; ELSA also feeds the European EDENT1FI consortium working toward early T1D detection across countries.1

References

  1. Quinn LM, et al. Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening — the EarLy Surveillance for Autoimmune diabetes (ELSA) study. Diabetic Medicine (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006551/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  2. The ELSA Study (official site), University of Birmingham / NHS. elsadiabetes.nhs.uk (accessed 2026). https://www.elsadiabetes.nhs.uk/ ↩

  3. Diabetes UK. Screening children for type 1 diabetes: The ELSA study. diabetes.org.uk (accessed 2026). https://www.diabetes.org.uk/our-research/about-our-research/our-funded-projects/midlands/type-1-diabetes-screening-elsa ↩ ↩2

  4. Ziegler AG, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany (Fr1da). JAMA (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990943/ ↩ ↩2

  5. Quinn LM, et al. Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study. BMJ Open Diabetes Research & Care (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429353/ ↩

  6. Quinn LM, et al. EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1). BMJ Open Diabetes Research & Care (2022). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024254/ ↩

  7. Quinn LM, et al. Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study. The Lancet Diabetes & Endocrinology (2026). https://pubmed.ncbi.nlm.nih.gov/41576975/ ↩

  8. Herold KC, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (TN-10). New England Journal of Medicine (2019). https://pubmed.ncbi.nlm.nih.gov/31180194/ ↩

  9. Diabetes UK. Groundbreaking immunotherapy drug teplizumab licensed in UK for delaying early stages of type 1 diabetes. diabetes.org.uk (2024). https://www.diabetes.org.uk/about-us/news-and-views/groundbreaking-immunotherapy-drug-teplizumab-licensed-uk-delaying-early ↩

What's next for this

  • →Feasibility results of UK general-population screening reported, providing a 'blueprint' for a national NHS programme · 2026
  • →NICE decision on NHS funding of teplizumab (delay therapy that strengthens the screening case) still pending